Full-Time

Field Reimbursement Manager

Kidney

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

Compensation Overview

$136k - $204k/yr

+ Bonus + Equity Grants

Company Does Not Provide H1B Sponsorship

South Carolina, USA + 2 more

More locations: Georgia, USA | Alabama, USA

In Person

Field-based role with 50-70% travel within assigned territory.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Word/Pages/Docs
Salesforce
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

People at Vertex Pharmaceuticals

People at Vertex Pharmaceuticals who can refer or advise you

Requirements
  • Bachelor’s degree in health care, life sciences or business field; advanced degree in business, healthcare, social services is a plus
  • Minimum 5+ years’ experience in sales, reimbursement, market access, specialty pharmacy, patient services, or field-based access roles
  • Deep understanding of benefits investigations, PA processes, appeals, coverage policies, and payer ecosystems
  • Payer knowledge and in-depth understanding of Medicare, Medicaid, and commercial insurance plans
  • Experience working with specialty biologics, rare disease therapies, or complex pharmacy benefit products
  • Account management experience, working directly with health care professionals and office staff to navigate complex access challenges
  • Ability to navigate payer portals, Customer Relationship Management systems, and field access tools
  • Strong communication, training, and relationship-building skills with provider office staff and internal patient support programs and vendor teams
  • Strong analytical skills: ability to derive insights from customer and internal team engagements
  • Ability to leverage data and reporting tools to manage caseload and prioritize patient needs
  • Comfortable working in a fast-paced, results-driven environment within a growing business unit
  • Experience developing and executing strategic business/account plans
  • Demonstrated ability to facilitate appropriate judgment in decision making and problem solving
  • Ability to travel 50-70% within assigned territory
  • Proficiency in Microsoft Outlook, Word, Excel, PowerPoint, Salesforce CRM
  • Valid driver's license and ability to meet safe driving requirements
  • Ability to satisfy and meet all health care industry representative credentialing requirements to gain and maintain entry into facilities and organizations that are in your assigned territory
Responsibilities
  • Compliantly establish strong connections with key nephrology office personnel, including members of the care team and administrative staff responsible for prior authorizations and patient access to specialty medications, to support patient access to prescribed medications
  • Partner with case management team to address escalated access issues; ensure coordinated handoffs using CRM triggers and workflows
  • Support timely patient access to their prescribed Vertex medicine by educating offices on copay, PAP, Bridge programs, and other affordability pathways
  • Provide timely follow-up on case status and ensure offices understand insurance documentation requirements
  • Maintain a comprehensive understanding of commercial and government prescription insurance coverage requirements for access and payer trends
  • Conduct on-site and virtual in-services to deliver compliant and comprehensive education on: Regional payer policies, formulary updates, and coverage nuances
  • PA/medical exception criteria, coding/billing (ICD‑10, CPT), and documentation requirements
  • Distribution pathways, hub services, enrollment processes, and reimbursement workflows
  • Conduct on-site and virtual training using approved payer guides, checklists, access tools, and workflow maps
  • Independently manage a multistate geographic region, prioritizing accounts based on patient need, payer dynamics, and KPSP demand
  • Adapt engagement with prescribing HCP offices based on existing office workflows and avoid introducing complexities or inefficiencies
  • Develop territory engagement plans reflecting local payer landscapes and practice resources to help minimize patient-specific access barriers
  • Adhere to strict non‑promotional guidelines; all engagements must be compliant with relevant legal/compliance/privacy guardrails
  • Maintain confidentiality of patient health information and act in compliance with all laws, regulations, and Vertex company policies
  • Apply program business rules and work instructions to deliver a consistent and compliant patient and customer experience
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

People at Vertex Pharmaceuticals

People at Vertex Pharmaceuticals who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Crinetics acquisition adds $5B peak sales from acromegaly drug PALSONIFY.
  • Alyftrek launch boosts cystic fibrosis sales 700% to $424 million globally.
  • Gene editing workforce expansion of 400% captures 85% success rate in blood disorders.

What critics are saying

  • Cystic fibrosis revenue concentration risks 40–60% pricing erosion from AbbVie competitor.
  • Exa-cel (CASGEVY) adoption stalls 45–65% due to cheaper Gilead cell therapies.
  • PALSONIFY fails 50–70% to hit $5B peak sales amid AbbVie oral therapy launch.

What makes Vertex Pharmaceuticals unique

  • Vertex dominates the cystic fibrosis market with near-monopoly pricing power.
  • Vertex uniquely combines RNA editing, gene therapy, and small molecule innovation.
  • Vertex leads in non-opioid acute pain treatment via suzetrigine NaV1.8 inhibitor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Massachusetts Business Alliance for Education
Jun 8th, 2026
MBAE honors rep. Alice Peisch and Vertex Pharmaceuticals for advancing educational opportunity.

MBAE honors rep. Alice Peisch and Vertex Pharmaceuticals for advancing educational opportunity. June 8, 2026 MBAE honored Representative Alice Hanlon Peisch and Vertex Pharmaceuticals at its annual Leadership in Education Awards luncheon for their outstanding contributions to expanding educational opportunity and advancing student success across Massachusetts. Representative Peisch received the MBAE Paul Reville Leadership in Education Award in recognition of more than two decades of public service and unwavering commitment to educational equity and opportunity. Since joining the Massachusetts House of Representatives in 2003, Peisch has been a leading advocate for educational excellence, equity, and accountability. As chair of the Joint Committee on Education from 2011 to 2023, she helped advance major reforms in school finance, special education, educator preparation, and literacy. She co-chaired the 2014 Foundation Budget Review Commission, whose recommendations helped shape the landmark Student Opportunity Act, and served on the National Assessment Governing Board, including as vice chair through 2024. The award was presented to Representative Peisch by Massachusetts Secretary of Education Stephen Zrike who along with Commissioner Pedro Martinez shared remarks during the event. The MBAE Jack Rennie Award for Business Impact in Education was presented to Vertex Pharmaceuticals and the Vertex Foundation for their commitment to advancing education, innovation, and community well-being. A leading corporate citizen in Massachusetts, Vertex partners with schools, nonprofits, and community organizations to expand access to STEAM (Science, Technology, Engineering, Arts, and Math) education, particularly for students from historically underrepresented and under-resourced communities. Through mentorship, hands-on learning experiences, and exposure to STEM careers, Vertex helps students envision pathways into science and innovation. MBAE's awards are named in honor of its co-founders, Paul Reville and Jack Rennie, who together led a five-year push for sweeping reform in the state's K-12 education system, resulting in the Massachusetts Education Reform Act of 1993. Reville later served as Massachusetts Secretary of Education. MBAE's annual awards luncheon celebrates the business community's commitment to excellence in public education.

Investing.com
Apr 13th, 2026
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026.

Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026. Published 04/13/2026, 06:16 AM (C) Reuters. Investing.com - Bank of America has reaffirmed Argenx (NASDAQ:ARGX) and Vertex Pharmaceuticals (NASDAQ:VRTX) as its top large-cap biotech picks for 2026, with price targets of $1,013 and $598, respectively. For Argenx, BofA cited strong commercial performance of Vvygart in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, driven by expansion into earlier treatment lines and growing real-world experience. The firm highlighted upcoming phase 3 results for efgartigimod in myositis in the third quarter and empasiprubart in multifocal motor neuropathy in the fourth quarter as potential catalysts. For Vertex, BofA emphasized the strength of the cystic fibrosis franchise in providing cash flow to support pipeline expansion. The firm identified the rare kidney disease franchise as a key long-term growth driver, noting positive data for povetacicept in IgA nephropathy. Among commercial small- and mid-cap picks, BofA selected KalVista Pharmaceuticals (NASDAQ:KALV) with a $32 price target and Rhythm Pharmaceuticals (NASDAQ:RYTM) with a $149 price target. KalVista's Ekterly was approved in July 2025 as the first on-demand hereditary angioedema therapy, while Rhythm's Imcivree became the first approved therapy for acquired hypothalamic obesity in March. For pre-commercial small- and mid-cap stocks, BofA named Ocular Therapeutix (NASDAQ:OCUL) with a $27 price target and Bicara Therapeutics (NASDAQ:BCAX) with a $35 price target as top picks. Should you invest $2,000 in VRTX right now? ProPicks AI evaluates VRTX alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if VRTX is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

National Today
Apr 11th, 2026
Fiduciary Alliance buys $2.2M stake in Vertex Pharmaceuticals

Fiduciary Alliance LLC purchased 4,828 shares of Vertex Pharmaceuticals during the fourth quarter, valued at approximately $2.19 million, according to a recent 13F filing with the Securities and Exchange Commission. The investment reflects confidence in the Boston-based biotechnology company, which specialises in developing treatments for serious diseases, particularly cystic fibrosis. Vertex's portfolio of CFTR modulators has transformed standards of care for many CF patients. Vertex's share price has risen over 20% in the past year as the company continues expanding its cystic fibrosis treatments and exploring new therapeutic areas. The investment signals institutional interest in Vertex's growth potential and drug pipeline.

GlobalData
Apr 8th, 2026
Halozyme and Vertex sign deal for Hypercon technology.

Halozyme and Vertex sign deal for Hypercon technology. Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments. Halozyme Therapeutics' subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former's Hypercon technology. Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics, aiming to reduce injection volume and facilitate at-home administration for patients. Vertex will make an upfront payment of $15m to Halozyme, along with potential future milestone payments. Halozyme will also receive royalties on net sales of any products that are developed using the technology. Halozyme Therapeutics president and CEO Helen Torley said: "This collaboration with Vertex underscores the versatility and potential of its Hypercon technology to enable small volume, patient-delivered next generation biologics. "Vertex is a proven innovator with deep expertise, and we believe Hypercon can play an important role in supporting improved ease of patient access to targeted biologics that have the potential to advance innovation for patients with serious diseases." Halozyme's Enhanze drug delivery technology, based on the enzyme rHuPH20, supports the subcutaneous administration of injected drugs and fluids to lower treatment burden and enhance convenience. Enhanze has been involved in over one million patient lives through ten commercialised products across more than 100 countries, and is licensed to companies such as AbbVie, Eli Lilly, Pfizer, Roche, Takeda, and ViiV Healthcare. Halozyme has expanded its drug delivery portfolio to include Hypercon, as well as Surf Bio's polymer-based hyperconcentration technology, broadening the possibilities for subcutaneous biologics delivery. In January 2026, Takeda announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter's Enhanze drug delivery technology. Give your business an edge with its leading industry insights.

The Pharma Letter
Apr 8th, 2026
Halozyme inks license agreement with Vertex.

Halozyme inks license agreement with Vertex. 8 April 2026 San Diego, USA-based Halozyme Therapeutics (Nasdaq: HALO) late yesterday announced it has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals (Nasdaq: VRTX). This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 17 November 2025 25 April 2025 14 September 2017 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 8 April 2026 7 April 2026 Company spotlight. A clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases characterized by abnormal appetite and metabolic disorders. More features in pharmaceutical. 8 April 2026 7 April 2026